AroCell AB (publ) (AROC.ST)
SEK 0.59
(-2.33%)
SEK 0.59
(-2.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -59.78 Million SEK | -1.87% |
| 2022 | -59.3 Million SEK | -17.26% |
| 2021 | -50.57 Million SEK | -110.27% |
| 2020 | -24.05 Million SEK | -15.99% |
| 2019 | -20.73 Million SEK | 0.1% |
| 2018 | -20.75 Million SEK | -20.21% |
| 2017 | -17.26 Million SEK | -87.09% |
| 2016 | -9.22 Million SEK | -23.3% |
| 2015 | -7.48 Million SEK | -16.77% |
| 2014 | -6.4 Million SEK | -72.34% |
| 2013 | -3.71 Million SEK | -18.25% |
| 2012 | -3.14 Million SEK | 10.26% |
| 2011 | -3.5 Million SEK | -67.59% |
| 2010 | -2.09 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -11.35 Million SEK | 33.76% |
| 2024 Q3 | -10.06 Million SEK | 24.43% |
| 2024 Q2 | -13.31 Million SEK | -17.26% |
| 2023 FY | -60.41 Million SEK | -1.87% |
| 2023 Q3 | -13.26 Million SEK | 14.34% |
| 2023 Q2 | -15.48 Million SEK | -13.28% |
| 2023 Q4 | -17.13 Million SEK | -29.2% |
| 2023 Q1 | -13.67 Million SEK | 17.29% |
| 2022 Q1 | -15.69 Million SEK | 21.49% |
| 2022 Q4 | -16.52 Million SEK | -49.34% |
| 2022 Q3 | -11.06 Million SEK | 30.89% |
| 2022 Q2 | -16.01 Million SEK | -2.03% |
| 2022 FY | -59.3 Million SEK | -17.26% |
| 2021 Q1 | -6.07 Million SEK | -1.1% |
| 2021 Q3 | -17.77 Million SEK | -164.23% |
| 2021 Q4 | -19.99 Million SEK | -12.47% |
| 2021 FY | -50.57 Million SEK | -110.27% |
| 2021 Q2 | -6.72 Million SEK | -10.68% |
| 2020 Q1 | -5.47 Million SEK | 9.27% |
| 2020 Q4 | -6.01 Million SEK | 5.63% |
| 2020 FY | -24.05 Million SEK | -15.99% |
| 2020 Q3 | -6.37 Million SEK | -2.84% |
| 2020 Q2 | -6.19 Million SEK | -13.17% |
| 2019 Q4 | -6.03 Million SEK | -34.08% |
| 2019 Q3 | -4.5 Million SEK | 8.44% |
| 2019 FY | -20.73 Million SEK | 0.1% |
| 2019 Q1 | -5.28 Million SEK | 3.21% |
| 2019 Q2 | -4.91 Million SEK | 7.04% |
| 2018 Q1 | -4.18 Million SEK | 27.35% |
| 2018 Q2 | -5.71 Million SEK | -36.59% |
| 2018 FY | -20.75 Million SEK | -20.21% |
| 2018 Q4 | -5.46 Million SEK | -1.16% |
| 2018 Q3 | -5.4 Million SEK | 5.46% |
| 2017 Q4 | -5.75 Million SEK | -56.51% |
| 2017 FY | -17.26 Million SEK | -87.09% |
| 2017 Q3 | -3.67 Million SEK | -2.0% |
| 2017 Q2 | -3.6 Million SEK | 14.65% |
| 2017 Q1 | -4.22 Million SEK | -62.39% |
| 2016 FY | -9.22 Million SEK | -23.3% |
| 2016 Q1 | -2.84 Million SEK | -73.13% |
| 2016 Q2 | -1.9 Million SEK | 33.08% |
| 2016 Q3 | -2.59 Million SEK | -36.17% |
| 2016 Q4 | -2.6 Million SEK | -0.46% |
| 2015 FY | -7.48 Million SEK | -16.77% |
| 2015 Q2 | -1.64 Million SEK | 31.58% |
| 2015 Q1 | -2.39 Million SEK | 14.96% |
| 2015 Q4 | -1.64 Million SEK | 9.1% |
| 2015 Q3 | -1.8 Million SEK | -10.12% |
| 2014 Q1 | -1.11 Million SEK | 28.68% |
| 2014 Q4 | -2.81 Million SEK | -165.41% |
| 2014 FY | -6.4 Million SEK | -72.34% |
| 2014 Q3 | -1.06 Million SEK | 25.05% |
| 2014 Q2 | -1.41 Million SEK | -27.43% |
| 2013 FY | -3.71 Million SEK | -18.25% |
| 2013 Q1 | -855 Thousand SEK | 16.91% |
| 2013 Q4 | -1.55 Million SEK | -253.54% |
| 2013 Q3 | -441 Thousand SEK | 48.96% |
| 2013 Q2 | -864 Thousand SEK | -1.05% |
| 2012 Q1 | -715 Thousand SEK | 38.2% |
| 2012 Q2 | -873 Thousand SEK | -22.1% |
| 2012 Q4 | -1.02 Million SEK | -94.52% |
| 2012 Q3 | -529 Thousand SEK | 39.4% |
| 2012 FY | -3.14 Million SEK | 10.26% |
| 2011 Q2 | -1.19 Million SEK | -76.89% |
| 2011 Q3 | -478 Thousand SEK | 59.97% |
| 2011 FY | -3.5 Million SEK | -67.59% |
| 2011 Q1 | -675 Thousand SEK | -14.98% |
| 2011 Q4 | -1.15 Million SEK | -142.05% |
| 2010 Q3 | -578 Thousand SEK | -4.9% |
| 2010 Q2 | -551 Thousand SEK | 0.0% |
| 2010 Q4 | -587.06 Thousand SEK | -1.57% |
| 2010 FY | -2.09 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | -56.5 Million SEK | -5.812% |
| Immunovia AB (publ) | -296.46 Million SEK | 79.834% |
| Prostatype Genomics AB (publ) | -39.3 Million SEK | -52.099% |
| SenzaGen AB | -14.74 Million SEK | -305.59% |
| Spermosens AB | -10.89 Million SEK | -448.779% |